This is a pivotal de-risking event for a single-asset biotech — the ORR improvement, PFS HR, and FDA alignment on Phase 3 design materially increase the probability of eventual approval in RAS-mutated mCRC (large unmet need, no approved RAS-targeted therapies outside KRAS G12C). Traders should watch the June 3 webcast for Phase 3 timeline details and any partnership signals. Given the $101M market cap and strong Phase 2 data, this stock could re-rate significantly as the market prices in the Phase 3 pathway.
Price Chart
Executive Summary
Cardiff Oncology announced positive Phase 2 data for onvansertib in first-line RAS-mutated mCRC at ASCO 2026, showing a 72.2% confirmed ORR vs 42.1% for SOC, and median PFS not yet reached. The company has aligned with the FDA on a registrational Phase 3 trial design, marking a key de-risking milestone that transforms the development pathway for this early-stage biotech.
Key Facts
- Phase 2 CRDF-004 trial met primary goal of selecting efficacious/safe dose (30 mg onvansertib + FOLFIRI/bevacizumab) for registrational program
- Confirmed ORR of 72.2% for onvansertib arm vs 42.1% for SOC alone — a 30% absolute improvement
- Median PFS not yet reached in either onvansertib (20 or 30 mg) + FOLFIRI/bev arms; nine of 14 patients remain on treatment
- PFS hazard ratio of 0.55 (BICR) and 0.57 (investigator) vs SOC
- End-of-Phase 2 meeting with FDA completed; registrational Phase 3 trial design aligned — randomized, controlled trial of onvansertib 30 mg + FOLFIRI/bev vs SOC
- No additive toxicities; onvansertib well-tolerated with infrequent Grade 3+ AEs
- Investor webcast scheduled for June 3, 2026 to review data and registrational plans
Financial Impact
Phase 2 efficacy signal (72.2% ORR vs 42.1% SOC) and FDA alignment on Phase 3 design are transformational for a clinical-stage biotech with $101M market cap — could enable partnership value or significantly increase valuation on Phase 3 initiation
Risk Factors
- Phase 3 trial may fail to replicate Phase 2 results — single-arm and small N in active arm (n=18) limits statistical reliability
- No efficacy advantage seen with FOLFOX backbone, limiting combinability
- Registrational trial enrollment and execution risk for a small company; may require partnership or financing
- Patient retention is early — median PFS not reached but data are immature; durability tail could still shrink
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305287 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 4w ago | Institutional Cluster | $1.33 $1.17 | ▲ +12.03% | ▲ +10.84% | $0.8486 (+36.20%) |
Sep 14, 2026 6w ago | 8-K | $1.31 $1.37 | ▲ +4.58% | ▲ +4.47% | $0.8486 (−35.22%) |
Aug 11, 2026 10w ago | Press Release | $0.9900 $0.8979 | ▲ +9.30% | ▲ +8.86% | $0.8486 (+14.28%) |
Jul 16, 2026 14w ago | Insider Cluster | $0.8800 $0.8381 | ▼ −4.76% | ▼ −4.07% | $0.8486 (−3.57%) |
Jul 16, 2026 14w ago | 8-K | $0.8745 $0.8381 | ▲ +4.16% | ▲ +2.49% | $0.8486 (+2.96%) |
Jul 16, 2026 14w ago | 424B5 | $0.8745 $0.8381 | ▲ +4.16% | ▲ +2.49% | $0.8486 (+2.96%) |
Jun 22, 2026 18w ago | Insider Cluster | $1.30 $1.25 | ▼ −3.85% | ▼ −1.78% | $0.8486 (−34.72%) |
Jun 11, 2026 19w ago | Institutional Cluster | $1.59 $1.18 | ▲ +25.79% | ▲ +26.22% | $0.8486 (+46.63%) |
Jun 3, 2026 20w ago | 8-K | $1.40 $1.48 | ▲ +5.71% | ▲ +9.53% | $0.8486 (−39.39%) |
Jun 2, 2026 21w ago | Press Release | $1.51 $1.53 | ▲ +1.32% | ▲ +4.29% | $0.8486 (−43.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers